LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer

详细信息    查看全文

• 作者：Shunji Takahashi ; Takayuki Kobayashi…
• 关键词：HER3 ; HER2 ; LJM716 ; Monoclonal antibody ; Phase I
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：79
• 期：1
• 页码：131-138
• 全文大小：436KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-0843
• 卷排序：79

文摘

PurposeHuman epidermal growth factor receptor 3 (HER3) has been identified as an important component of many receptor tyrosine kinase-driven cancers. LJM716 is a human IgG monoclonal antibody that binds HER3, trapping it in an inactive conformation. In this study, a phase I dose escalation was performed with a primary objective to establish the maximum tolerated dose and/or the recommended dose of LJM716 in Japanese patients with selected advanced solid tumors. Secondary objectives included the evaluation of the safety and tolerability, preliminary antitumor activity, and pharmacokinetics of LJM716 in Japanese patients.